8-KEarnings & ResultsExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Financial Results (Jan 28, 2005)

Filed January 28, 2005For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on January 27, 2005, to announce its earnings for the quarter and year ended December 31, 2004. The report includes a press release detailing these results and clarifies that certain non-GAAP financial measures are presented to offer insights into the company's core business performance by excluding specific unusual or infrequent items. Investors should note that the company is providing adjustments for items such as the gain on Eyetech warrants, a make-whole payment for convertible debt redemption, an in-process R&D charge from the Triangle Pharmaceuticals acquisition, a vendor dispute settlement reimbursement, and impairment charges on long-lived assets. Management believes these adjustments provide a clearer view of ongoing results and trends relevant to the core business.

Key Highlights

  • 1Gilead Sciences announced its financial results for the fourth quarter and full year ended December 31, 2004, via a press release filed with the 8-K.
  • 2The company is presenting non-GAAP financial measures alongside GAAP results.
  • 3These non-GAAP measures exclude several significant items impacting the reported financial statements.
  • 4Key adjustments include a $20.6 million gain on Eyetech warrants and a $7.4 million make-whole payment for convertible debt redemption.
  • 5Other excluded items consist of an $488.6 million in-process R&D charge from the Triangle Pharmaceuticals acquisition, a $13.2 million R&D reimbursement from a vendor settlement, and $10.9 million in impairment charges.
  • 6Gilead's management uses these non-GAAP figures to monitor and evaluate ongoing results and believes they are useful for investors to understand core business trends.
  • 7The 8-K filing primarily serves to furnish the earnings press release (Exhibit 99.1) as supplementary financial information.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce and provide Gilead Sciences' earnings results for the quarter and full year ended December 31, 2004. It includes a press release detailing these results and management's commentary.

Gilead is providing non-GAAP financial measures because management uses this information to monitor and evaluate ongoing results and trends. They believe these adjusted figures offer investors a more useful insight into the company's core business performance by excluding unusual, infrequent, or non-cash transactions.

Major adjustments included a $20.6 million fair value gain on Eyetech warrants, a $7.4 million make-whole payment for convertible debt redemption, an $488.6 million in-process R&D charge from the Triangle Pharmaceuticals acquisition, a $13.2 million reimbursement for R&D expenses from a vendor settlement, and $10.9 million in non-cash impairment charges on certain assets.

The Triangle Pharmaceuticals acquisition in Q1 2003 resulted in a significant $488.6 million charge for in-process R&D. The Eyetech Pharmaceuticals IPO in Q1 2004 led to a $20.6 million fair value gain on warrants Gilead held. These were substantial, non-recurring events that management sought to isolate for clarity on ongoing operations.